For example, anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy for hematologic malignancies has undoubtedly achieved impressive results, and the key to its success lies in the selection of the specific target (CD19, expressed in more than 95% of B-cell malignant tumors) as well as in the continuous innovation of the CAR structure [102]. The gene discussed is CD19; the disease is hematologic disorder.